Last week, the biotech market experienced extreme volatility, driven by sharp policy reversals on tariffs, aggressive trading behavior, and increasing concerns about the sector’s viability, though some signs point to potential recovery later in 2025. Data, in part from DealForma, highlights M&A activity by private equity firms alongside broader market trends. Read the article here
